...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Asthma treatment: 'magic bullets which seek their own targets'.
【24h】

Asthma treatment: 'magic bullets which seek their own targets'.

机译：哮喘治疗：“寻找自己目标的神奇子弹”。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The most fascinating options of the new asthma treatments are probably represented by monoclonal antibodies. In fact, these molecules are virtually able to interact with whatever specific antigen. Anyway, it is mandatory to understand the limits of this group of molecules, in terms of both efficacy and safety. In this review, we have analyzed different ways of interfering along the course of the cascade of the allergic reaction, targeting different molecules (CD4, TNF-alpha, IL-4, IL-5, IL-10, IL-12, endothelial adhesion molecules, IgE), showing the efficacy and the risks of each kind of treatment. In the end, we focused our attention on omalizumab, the monoclonal antibody targeting IgE. Although with some restrictions, represented by the high costs and the limitation of its use only to a specific subset of patients affected by allergic asthma, at present anti-IgE appear to be the only 'magic bullet' for the treatment of allergic asthma. In fact, it proved to reduce exacerbations and symptom scores, and to improve quality of life, with a very good safety profile.
机译：新的哮喘治疗方法中最引人入胜的选择可能是单克隆抗体。实际上，这些分子实际上能够与任何特定抗原相互作用。无论如何，必须从功效和安全性两方面了解这组分子的局限性。在这篇综述中，我们分析了过敏反应级联过程中的不同干扰方式，靶向不同分子（CD4，TNF-α，IL-4，IL-5，IL-10，IL-12，内皮粘附分子（IgE），显示出每种治疗的功效和风险。最后，我们将注意力集中在针对IgE的单克隆抗体omalizumab上。尽管存在一定的局限性，以高昂的费用和仅将其用于特定人群的变应性哮喘为代表，但目前抗IgE似乎是治疗变应性哮喘的唯一“灵丹妙药”。实际上，事实证明，它具有很好的安全性，可减少病情加重和症状评分，并改善生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号